Detalhe da pesquisa
1.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499670
2.
Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.
Allergol Int
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594174
3.
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.
J Formos Med Assoc
; 121(12): 2430-2437, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153210
4.
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Cancer
; 127(24): 4585-4593, 2021 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415578
5.
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Liver Int
; 41(11): 2759-2767, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34173317
6.
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan.
J Formos Med Assoc
; 120(11): 2023-2031, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33422398
7.
Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study.
Int J Cancer
; 147(7): 1904-1916, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32196659
8.
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
Oncologist
; 25(12): e1921-e1929, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33017497
9.
Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
J Am Acad Dermatol
; 90(2): 368-369, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690021
10.
Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors: A cohort study.
J Am Acad Dermatol
; 90(4): 814-815, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38065319
11.
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
J Formos Med Assoc
; 117(2): 153-163, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28392193
12.
The effect of abdominal massage in reducing malignant ascites symptoms.
Res Nurs Health
; 38(1): 51-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25558030
13.
Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
Int J Colorectal Dis
; 28(11): 1535-46, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23784051
14.
Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Eur J Cancer
; 195: 113286, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968194
15.
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study.
Asia Pac J Clin Oncol
; 19(6): 672-680, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36855017
16.
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
J Hepatol
; 56(5): 1097-1103, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22245891
17.
Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer.
Front Cardiovasc Med
; 9: 880956, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35990963
18.
Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis.
Front Pharmacol
; 12: 693009, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34267662
19.
Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
Sci Rep
; 11(1): 15370, 2021 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321583
20.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 10(1): 25-34, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19095497